Brokerages Set BioLife Solutions, Inc. (NASDAQ:BLFS) Price Target at $27.50

Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) have been given an average rating of “Buy” by the six ratings firms that are presently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $27.50.

A number of analysts have recently weighed in on BLFS shares. Craig Hallum raised their target price on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. TD Cowen lifted their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Northland Securities lifted their price objective on BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Finally, HC Wainwright lowered their price objective on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research report on Monday, November 18th.

Insider Transactions at BioLife Solutions

In other BioLife Solutions news, EVP Aby J. Mathew sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $23.28, for a total value of $232,800.00. Following the sale, the executive vice president now owns 317,716 shares in the company, valued at approximately $7,396,428.48. The trade was a 3.05 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CRO Garrie Richardson sold 3,070 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $25.12, for a total value of $77,118.40. Following the completion of the sale, the executive now owns 114,773 shares in the company, valued at $2,883,097.76. The trade was a 2.61 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 71,313 shares of company stock worth $1,572,899. 2.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On BioLife Solutions

Several institutional investors have recently bought and sold shares of the company. Barclays PLC lifted its stake in BioLife Solutions by 20.1% in the 3rd quarter. Barclays PLC now owns 64,423 shares of the medical equipment provider’s stock valued at $1,613,000 after acquiring an additional 10,803 shares in the last quarter. Geode Capital Management LLC lifted its stake in BioLife Solutions by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock valued at $21,107,000 after acquiring an additional 18,473 shares in the last quarter. State Street Corp raised its stake in shares of BioLife Solutions by 7.3% during the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after purchasing an additional 95,788 shares in the last quarter. Stifel Financial Corp raised its stake in shares of BioLife Solutions by 5.4% during the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock worth $325,000 after purchasing an additional 670 shares in the last quarter. Finally, Mark Sheptoff Financial Planning LLC bought a new stake in shares of BioLife Solutions during the 3rd quarter worth approximately $28,000. Institutional investors own 93.24% of the company’s stock.

BioLife Solutions Stock Down 1.7 %

Shares of NASDAQ BLFS opened at $26.81 on Friday. BioLife Solutions has a 52-week low of $12.45 and a 52-week high of $28.88. The stock has a market cap of $1.24 billion, a PE ratio of -25.29 and a beta of 1.91. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The business has a fifty day moving average of $24.27 and a two-hundred day moving average of $23.28.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.